Michele Tavecchio (Former)
1 – 24 of 24
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma
(
- Contribution to journal › Article
- 2021
-
Mark
Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma
(
- Contribution to journal › Article
- 2016
-
Mark
Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development
(
- Contribution to journal › Article
- 2015
-
Mark
Deletion of Cyclophilin D Impairs β-Oxidation and Promotes Glucose Metabolism
(
- Contribution to journal › Article
-
Mark
Adaptive mitochondrial reprogramming and resistance to PI3K therapy
(
- Contribution to journal › Article
- 2014
-
Mark
Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks
(
- Contribution to journal › Article
-
Mark
DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin
(
- Contribution to journal › Article
- 2013
-
Mark
Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility
(
- Contribution to journal › Article
- 2012
-
Mark
Chk2 phosphorylation of survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in cancer
(
- Contribution to journal › Article
-
Mark
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
(
- Contribution to journal › Article
-
Mark
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
(
- Contribution to journal › Article
- 2011
-
Mark
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
(
- Contribution to journal › Article
- 2010
-
Mark
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells
(
- Contribution to journal › Article
-
Mark
The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo
(
- Contribution to journal › Article
- 2009
-
Mark
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
(
- Contribution to journal › Article
-
Mark
The expression of the DeltaNp73beta isoform of p73 leads to tetraploidy
(
- Contribution to journal › Article
- 2008
-
Mark
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks : significance for the cytotoxic and antiproliferative activity
(
- Contribution to journal › Article
-
Mark
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil
(
- Contribution to journal › Article
-
Mark
Role of homologous recombination in trabectedin-induced DNA damage
(
- Contribution to journal › Article
-
Mark
Multi-parametric flow cytometric cell cycle analysis using TO-PRO-3 iodide (TP3) : detailed protocols
(
- Contribution to journal › Article
- 2007
-
Mark
Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach
(
- Contribution to journal › Article
-
Mark
Modulation of gene transcription by natural products--a viable anticancer strategy
(
- Contribution to journal › Article
- 2006
-
Mark
Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma : Role of retinoic acid receptor gamma and retinoid-independent pathways
(
- Contribution to journal › Article
- 2004
-
Mark
New drugs from the sea
(
- Contribution to journal › Article